Study of PK1 Doxorubicin in Cancer Patients
Author Information
Author(s): Thomson A H, Vasey P A, Murray L S, Cassidy J, Fraier D, Frigerio E, Twelves C
Primary Institution: Department of Medicine & Therapeutics, University of Glasgow
Hypothesis
The study aims to determine the pharmacokinetics of PK1-doxorubicin in patients with solid tumors.
Conclusion
The pharmacokinetics of PK1-doxorubicin were best described by a biexponential model, showing specific clearance and volume parameters.
Supporting Evidence
- Doxorubicin pharmacokinetics were determined in 33 patients.
- A population approach was used due to assay constraints.
- Bound concentrations were best described by a biexponential model.
- The final model included specific clearance and volume parameters.
- Distribution and elimination half-lives were estimated.
Takeaway
Researchers gave a new drug to cancer patients and studied how it moves and works in their bodies.
Methodology
A population pharmacokinetic approach was used to analyze the drug's behavior in patients receiving various doses.
Limitations
Assay constraints limited data at lower doses, affecting conventional analysis.
Participant Demographics
Patients with solid tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website